Thursday, March 21, 2019
7:30 am – 12:00 pm
Free for RWC Main Program Attendees!

Thursday's Unplugged Program

7:30 am – 7:35 am
Opening Comments
Program Chairs: Pravin U. Dugel, MD; Peter K. Kaiser, MD; Baruch D. Kuppermann, MD, PhD
7:35 am – 7:57 am
Keynote Lecture: Building a Platform Gene Therapy Company: The Last 10 Years
Ken Mills – President and Chief Executive Officer of REGENXBIO
7:57am – 8:24 am
Next Generation Anti-VEGF Panel
Moderator: Pravin U. Dugel, MD
8:24 am – 8:51 am
New Pathways in Retinal Diseases: AMD
Moderator: Peter K. Kaiser, MD
8:51 am – 9:18 am
New Pathways in Retinal Diseases: Diabetes
Moderator: Baruch D. Kuppermann, MD, PhD
9:18 am – 9:40 am
Keynote Lecture: FDA Perspective
Wiley Chambers, MD – Supervisory Medical Officer, Ophthalmology Food and Drug Administration (FDA)
9:40 am – 10:07 am
Dry AMD Treatment Panel
Moderator: Peter K. Kaiser, MD
10:07 am – 10:34 am
Gene and Cell Therapy Panel
Moderator: Pravin U. Dugel, MD
10:34 am – 10:56 am
Keynote Lecture: Investor Perspective
Eliot Lazar, MD, MS, MBA – President, elCON Medical Enterprises, Inc.
10:56 am – 11:18 am
New Therapies in Uveitis Panel
Moderator: Baruch D. Kuppermann, MD, PhD
11:18 am – 11:40 am
Changing Landscape of the Retina Practice and How it Will Affect Drugs
Moderator: Pravin U. Dugel, MD
11:40 am – 12:00 pm
Keynote Lecture: Large Pharma Perspective
Joseph C. Papa – Chairman of the Board and Chief Executive Officer, Bausch Health
Please note: RWC Unplugged is not approved for AMA PRA Category 1 Credit(s)™.